Home / The Market / The Wall Street Journal: How the Kodak generic-drug ingredients deal developed, and why it fell apart: a snapshot

The Wall Street Journal: How the Kodak generic-drug ingredients deal developed, and why it fell apart: a snapshot

On a white board in his office earlier this year, Trump trade adviser Peter Navarro made a list of potential companies that could manufacture pharmaceuticals in the U.S.

He separated them into three columns, one for each stage of the production process. Eastman Kodak Co. stood out, overlapping two of the three columns. The way Navarro saw it, he recalled, Kodak could help produce the ingredients to jump-start generic drug production and ease the country’s reliance on foreign supplies.

Let’s block ads! (Why?)

MarketWatch.com – Top Stories

About

Check Also

: ‘We shouldn’t be complacent’: Suicide deaths fell during the 2020 pandemic — but what caused the decline?

Preliminary estimates suggest that suicide deaths declined amid the unprecedented mental-health and economic challenges last …